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Tumor  development  has  been  regarded  as  a 
multistep process that involves tumor initiation, 
promotion, and progression. Whereas tumor ini-
tiation is considered to be dependent on genetic 
alterations that increase survival and prolifera-
tion of single cells, various paracrine and auto-
crine mechanisms stimulate the growth of these 
initiated tumor cells during tumor promotion, 
and the growing cluster of tumor cells finally 
develops malignant characteristics, including in-
vasion and metastatic growth in the course of 
progression (Pitot, 1993; Balkwill et al., 2005).
As the distance of individual cells to blood 
vessels  increases  during  tumor  growth,  these 
cells are depleted of oxygen and nutrients and 
therefore depend on the recruitment of new ves-
sels to the tumor site through angiogenesis 
(Ferrara, 2009). After the proposition of vascu-
larization as an essential component of tumor 
growth and the inhibition of angiogenesis as a 
promising strategy for the treatment of cancer by 
Folkman (1971), subsequent research on various 
pro- and antiangiogenic molecules finally led to 
the approval of the first antiangiogenic substance, 
bevacizumab, for first-line treatment  of  meta-
static colorectal cancer (CRC; Kerbel, 2008).
Bevacizumab  is  a  humanized  monoclonal 
antibody  directed  against  vascular  endothelial 
growth factor (VEGF), a molecule that has been 
regarded as the major mediator of tumor angio-
genesis. VEGF is expressed by most types of 
cancer after the activation of hypoxia-inducible 
transcription factors 1 and 2 in response 
to  hypoxia  and  metabolic  stress  (Semenza, 
2003). Although VEGF is a ligand for VEGF 
receptor 2 (VEGFR2) and VEGFR1, VEGF 
signaling in angiogenesis is mainly mediated 
through  VEGFR2, a receptor tyrosine kinase that 
is expressed at elevated levels by endothelial cells 
CORRESPONDENCE  
M.F. Neurath: 
markus.neurath@uk-erlangen.de
Abbreviations used: AOM, 
azoxymethane; CAC, colitis-
associated cancer; CRC, 
colorectal cancer; DSS, dextran 
sodium sulfate; IBD, inflamma-
tory bowel disease; IEC, intesti-
nal epithelial cell; STAT3, signal 
transducer and activator of tran-
scription 3; VEGF, vascular 
endothelial growth factor; 
VEGFR, VEGF receptor.
VEGF receptor signaling links inflammation 
and tumorigenesis in colitis-associated cancer
Maximilian J. Waldner,1,2 Stefan Wirtz,1,2 André Jefremow,2  
Moritz Warntjen,2 Clemens Neufert,1 Raja Atreya,1 Christoph Becker,1,2 
Benno Weigmann,1,2 Michael Vieth,3 Stefan Rose-John,4  
and Markus F. Neurath1,2
1Department of Medicine I, University of Erlangen-Nuremberg, D-91054 Erlangen, Germany
2Institute of Molecular Medicine, University of Mainz, D-55131 Mainz, Germany
3Institute of Pathology, Klinikum Bayreuth, D-95445 Bayreuth, Germany
4Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, Medical Faculty, D-23098 Kiel, Germany
Whereas the inhibition of vascular endothelial growth factor (VEGF) has shown promising 
results in sporadic colon cancer, the role of VEGF signaling in colitis-associated cancer 
(CAC) has not been addressed. We found that, unlike sporadic colorectal cancer and control 
patients, patients with CAC show activated VEGFR2 on intestinal epithelial cells (IECs).  
We then explored the function of VEGFR2 in a murine model of colitis-associated colon cancer 
characterized by increased VEGFR2 expression. Epithelial cells in tumor tissue expressed 
VEGFR2 and responded to VEGF stimulation with augmented VEGFR2-mediated prolifera-
tion. Blockade of VEGF function via soluble decoy receptors suppressed tumor development, 
inhibited tumor angiogenesis, and blocked tumor cell proliferation. Functional studies 
revealed that chronic inflammation leads to an up-regulation of VEGFR2 on IECs. Studies 
in conditional STAT3 mutant mice showed that VEGFR signaling requires STAT3 to promote 
epithelial cell proliferation and tumor growth in vivo. Thus, VEGFR-signaling acts as a 
direct growth factor for tumor cells in CAC, providing a molecular link between inflamma-
tion and the development of colon cancer.
© 2010 Waldner et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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in colitis-associated neoplasias, we exposed wild-type mice to a 
mouse model of CAC using AOM+DSS (Fig. 1 A). In these 
experiments, significantly elevated levels of VEGF were de-
tected in the plasma and tumor tissue of tumor-bearing mice as 
compared with control mice (Fig. 1 B). Furthermore,  VEGFR2 
mRNA expression was increased in tumor cells (Fig. 1 C) and 
VEGFR2 protein levels were elevated in the inflamed colon 
and tumors of AOM+DSS-treated animals as compared with 
control animals (Fig. 1 D). Subsequent studies aiming at the 
identification of cells expressing VEGFR2 revealed marked 
VEGFR2 expression on IECs from tumor tissue, whereas 
little or no VEGFR2 expression was seen on control IECs 
(Fig. 1, D and E). Consistently, IECs isolated from tumors ex-
pressed significantly higher amounts of VEGFR2 mRNA as 
compared with control IECs (Fig. S1 A). Collectively, these 
findings indicated the expression of VEGFR2 on IECs from 
tumor tissue in AOM+DSS colitis.
To further analyze the expression of VEGF and VEGFR2 
during the course of AOM+DSS colitis, we exposed transgenic 
mice with a luciferase reporter driven by the promoter for 
VEGF or VEGFR2 to the AOM+DSS protocol. In these mice, 
VEGF and VEGFR2 promoter activity was paralleled by intes-
tinal inflammation with strong luminescence signals in the 
whole abdominal region, suggesting a role for VEGF and 
VEGFR2 signaling before tumor development (Fig. 1 F). 
Quantification of luminescence revealed a significant induction 
of both  VEGF and  VEGFR2 promoter activity in AOM+DSS-
treated mice during the course of the disease (Fig. 1 F).
To identify the cellular source of VEGFR2 expression, we 
performed immunohistochemical double staining for VEGFR2 
with markers of IECs (E-Cadherin), vascular endothelial cells 
(CD31), granulocytes (MPO), macrophages (F4/80), and CD4+ 
T cells. In these studies, expression of VEGFR2 in colitis- 
associated neoplasias was seen on CD31-expressing cells.   
In contrast, F4/80 and CD4-expressing cells showed little or no 
staining for VEGFR2. Furthermore, we noted marked ex-
pression of VEGFR2 on IECs in tumor tissue, whereas IECs in 
control mucosa showed no staining (Fig. 2; Fig. S1 B for controls). 
VEGFR2  expression  was  mainly  localized  at  the  basolateral 
membrane of tumor IECs. In contrast to VEGFR2, no staining 
of IECs was noted with an anti-VEGFR1 antibody, although 
some stroma cells showed staining for VEGFR1 (Fig. S1 C).
To further evaluate a functional role for  VEGFR2 on IECs, 
we performed immunohistochemistry for phospho-VEGFR2 
(pVEGFR2) and E-Cadherin. It was found that pVEGFR2 is 
expressed  on  tumor  epithelial  cells  in AOM+DSS-treated 
mice (Fig. 2), consistent with the idea that functionally active 
VEGFR2 is expressed by IEC in colonic tumors. In addition 
to VEGFR2, we analyzed the expression of VEGF in various 
cell subsets using immunohistochemical double staining.  VEGF 
was expressed in IECs and stroma cells, suggesting an activa-
tion of the VEGF–VEGFR2 pathway in AOM+DSS-treated 
animals (Fig. S2 A).
Because a role for VEGFR2 on IEC has not been de-
scribed so far in human intestinal inflammation and tumor de-
velopment, we additionally conducted immunohistochemistry 
(Shibuya and Claesson-Welsh, 2006). The activation of VEGFR2 
on endothelial cells results in their proliferation, migration, and 
increased survival and promotes vascular permeability. Although 
VEGF has a 10 times higher affinity for VEGFR1 in compari-
son to VEGFR2, the role of VEGFR1 in angiogenesis remains 
to be defined (Cao, 2009).
In addition to tumor development, growing evidence sup-
ports a role for angiogenesis and VEGF in the pathogenesis of 
chronic inflammatory disorders such as rheumatoid arthritis, 
psoriasis, and inflammatory bowel disease (IBD; Costa et al., 
2007). VEGF is not only released by various cells of the im-
mune system at the site of inflammation to induce angiogen-
esis but also directly activates immune cells as part of a positive 
feedback loop (Yoo et al., 2008; Scaldaferri et al., 2009).
Interestingly, chronic inflammation markedly increases the 
risk for the development of cancer, as seen in patients with 
IBD (Clevers, 2004; Zisman and Rubin, 2008), and therefore 
angiogenesis and VEGF signaling might pose an important link 
between inflammation and tumor development. However, the 
molecular mechanisms that lead to cancer in chronic inflam-
mation and the role of angiogenesis in inflammation-associated 
cancer remain poorly understood.
In the present study, we analyzed the role of angiogenesis 
and VEGF signaling in a mouse model of colitis-associated 
cancer (CAC) using azoxymethane (AOM) and dextran sodium 
sulfate (DSS) to study the interplay between inflammation, 
angiogenesis, and  VEGF signaling during tumor development. 
In these studies, tumor growth was paralleled by alterations 
of the microvascular architecture and increased expression of 
VEGF and VEGFR2. Furthermore, inhibition of VEGF sig-
naling through administration of VEGF-Trap, a soluble decoy 
receptor made from extracellular domains of VEGFR1 and 
VEGFR2, or an adenoviral vector expressing sVEGFR1, re-
duced tumor growth. Tumor cells highly expressed VEGFR2, 
and activation of this receptor resulted in increased tumor 
proliferation in a STAT3-dependent manner. The up-regulation 
of VEGFR2 could not only be observed on tumor cells but 
also on intestinal epithelial cells (IECs) during colitis and was 
mediated by the proinflammatory cytokine IL-6, which has 
been shown to be a strong promoter of tumor growth in ex-
perimental CAC (Becker et al., 2004).
These data suggest that VEGF acts as a direct link between 
inflammation and cancer development, and provide a rationale 
for the use of anti-VEGF therapeutics in chronic IBDs with an 
increased risk of tumor development. Additionally, cancer re-
sponse rates to anti-VEGF therapeutics might be influenced 
by VEGFR2 expression on the tumor cells themselves.
RESULTS
VEGFR2 is up-regulated on vascular endothelial cells  
and epithelial cells in mouse and human CAC
Although VEGF signaling has been identified as key factor in 
the pathogenesis of sporadic colorectal tumors in mice and 
humans (Jain et al., 2006; Boquoi et al., 2009; Grothey and 
Galanis, 2009), little is known about the function of VEGF in 
colitis-associated tumors. To analyze the role of VEGF signaling JEM VOL. 207, December 20, 2010 
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IECs, whereas VEGFR2 was mainly 
restricted to endothelial cells in healthy 
mucosa  and  CRC.  In  contrast  to 
VEGFR2, no staining for VEGFR1 on 
human IECs in IBD and CAC was 
noted (Fig. S1 D).
In addition, marked expression of pVEGFR2 on IECs 
was observed in IBD and CAC (Fig. 3 B), whereas increased 
expression of VEGF was noted in stroma cells and IECs in 
IBD and CAC patients (Fig. S2 B). The expression of VEGFR2 
on epithelial cells might be a consequence of chronic inflam-
mation as observed in IBD and CAC patients consistent with 
the hypothesis that activation of this receptor on epithelial 
cells might have a previously unrecognized function.
for VEGFR2  and  pVEGFR2  on  human  tissue  samples   
obtained from patients with IBD (Crohn’s disease and ulcer-
ative colitis), CAC, and sporadic CRC in comparison to control 
samples. Whereas VEGFR2 expression was restricted to en-
dothelial cells in control tissue, we found an increased expres-
sion of VEGFR2 in IBD and CAC, and this increase was more 
pronounced  as  compared  with  CRC  (Fig.  3 A). Again, 
VEGFR2 expression in IBD patients could be observed on 
Figure 1.  Up-regulation of VEGF and 
VEGFR2 expression through intestinal 
inflammation in the AOM+DSS-induced 
mouse model of CAC. (A) Mouse CAC is 
induced through the injection of AOM at day 
one, followed by three cycles of DSS in the 
drinking water and two weeks with normal 
drinking water. (B) Plasma and tissue levels of 
VEGF were analyzed from AOM+DSS-treated 
animals at indicated time points. Data show 
mean values ± SD (n = 5 per group) and are 
representative of two different experiments. 
Furthermore, tissue VEGF is increased in  
tumors in comparison to healthy mucosa. 
Data represent mean values ± SD (n = 7 per 
group). *, P < 0.05. (C) Quantitative PCR of 
VEGFR2 mRNA in tumor cells and normal 
epithelial cells of untreated animals. Data 
represent mean values ± SD (n = 4 per group) 
and are relative to Hprt1 mRNA. The experi-
ment was performed twice with similar re-
sults. *, P < 0.05. (D) Protein lysates from 
control colon, inflamed colon, and tumor 
tissue of AOM+DSS-treated mice were ana-
lyzed by immunoblot. Actin served as loading 
control. Data are representative of three inde-
pendent experiments. (E) FACS analysis of 
isolated IECs from tumor and control tissue. 
IECs were isolated as specified in Material and 
methods and stained for E-Cadherin and 
VEGFR2. Histograms are gated on E-Cadherin+ 
cells. One representative experiment out of 
three is shown. (F) Transgenic mice with a 
luciferase reporter driven by the promoter for 
VEGF (top) or VEGFR2 (bottom) were treated 
with AOM+DSS. Top images show one repre-
sentative mouse out of nine independent 
experiments at several time points. Lumines-
cence is illustrated with photons/sec/cm2/sr as 
indicated by the false-color chart. (bottom) 
Quantification of data was performed by ana-
lyzing the total flux of photons/second in the 
abdominal regions of experimental animals at 
indicated time points. Data represent mean 
values ± SD (n = 8 per group). *, P < 0.05.2858 VEGFR links inflammation and tumorigenesis | Waldner et al.
(Becker et al., 2004). Treatment of mice with both VEGF-Trap 
and sVEGFR1 resulted in decreased tumor scores, mainly 
because of reduced tumor numbers, whereas there was no dif-
ference concerning colonic inflammation upon endoscopy 
between treated groups and control groups (Fig. 4 B). In addi-
tion, optical contrast endoscopy was used to detect alterations of 
the vessel architecture upon VEGF blockade. “Abnormal” pat-
terns of tumor vessels are regarded as a sign of tumor angiogen-
esis, and antiangiogenic therapy has been shown to normalize 
alterations of the tumor vasculature (Jain, 2005). Optical con-
trast endoscopy revealed a reduced density of superficial vessels 
on tumors of VEGF-Trap–treated animals (Fig. 4 C).
To analyze the functional architecture of microvessels of 
the intestinal mucosa in more detail, we further applied confo-
cal in vivo endoscopy of the colon after i.v. injection of the 
plasma marker FITC-dextran to optical contrast endoscopy 
(Fig. 4 C and Fig. S3 C). We used a confocal laser probe that 
could be fed through the working sheet of our endoscope and 
enabled us to directly position the probe on an area of interest 
and obtain microscopic pictures of the vasculature. This so-
called endomicroscopy revealed a more organized architecture 
of the mucosal vasculature upon VEGF blockade in compari-
son to the more “chaotic” vessel architecture in the control 
group. To quantify these alterations, we used the assessment of 
the fractal dimension for the description of the pathological 
The inhibition of VEGF-signaling reduces tumor growth  
in experimental CAC
In subsequent experiments, we aimed at the functional char-
acterization of VEGF by blocking VEGF activity in vivo.   
In these studies, we used optical contrast endoscopy, a tech-
nique that is increasingly being used in the clinics for the di-
agnosis of intestinal tumors upon endoscopy (Emura et al., 
2008). Optical contrast endoscopy enabled us to detect altera-
tions of the vessel architecture at an early stage, small neoplastic 
lesions, and thereby facilitated identification and quantifica-
tion of tumors (Fig. S3 A). Tumors in AOM+DSS-treated mice 
showed enhanced expression of integrin v3 (Fig. S3 B), a 
receptor that is involved in the regulation of angiogenesis 
(Avraamides et al., 2008), as demonstrated by in vivo multi-
spectral fluorescence imaging.
To further examine the functional role of  VEGF in vivo, an-
imals were evaluated at week 4 of the AOM+DSS protocol for 
tumor growth using optical contrast endoscopy and allocated to 
groups with balanced tumor scores (Fig. 4 A). Individual groups 
were then treated with VEGF-Trap or soluble VEGFR1 
(sVEGFR1) and their respective controls (hFc vs. VEGF-Trap/
sVEGFR1 vs. LacZ expressing vector) to assess the effects of 
VEGF blockade on tumor growth. During the whole experi-
mental protocol, tumor development and growth were evalu-
ated repeatedly using high-resolution endoscopy in living mice 
Figure 2.  VEGFR2 is up-regulated and activated in tumor cells in a mouse model of CAC. Tumors and normal mucosa of AOM+DSS-treated 
animals were analyzed by confocal microscopy with antibodies specific for the indicated proteins. L, luminal side of intestinal crypt. Images show repre-
sentative images out of five experiments. Bars, 25 µm.JEM VOL. 207, December 20, 2010 
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in VEGF-Trap and control groups (unpublished data). How-
ever, there was a comparable infiltration of tumors with 
F4/80+ cells and CD4+ T cells in both groups (Fig. 5 A). Fur-
thermore, no difference in cleaved caspase-3 staining in stroma 
cells was noted between the groups, suggesting that VEGF-
Trap does not directly control apoptosis of these cells. In 
contrast, a marked reduction in the number of proliferating 
epithelial  cells  was  noted  upon VEGF-Trap  treatment,  as 
shown by E-Cadherin/Ki67 double staining (Fig. 5 A). Quan-
tification of Ki67+ cells revealed that tumors of control ani-
mals had statistically significant higher numbers of proliferating 
epithelial cells in comparison to VEGF-Trap–treated animals 
(Fig. 5 B). As these results were consistent with the idea that 
VEGF directly controls proliferation of IECs in tumor tissue 
via VEGFR2, we incubated tumor tissues of wild-type mice 
exposed to the AOM+DSS protocol to VEGF (250 ng/ml) 
in a tissue culture. In comparison to culture medium alone, 
VEGF treatment increased the number of proliferating epi-
thelial cells in tumor culture as revealed by E-Cadherin/Ki67 
staining (Fig. 5 C).
To analyze the role of  VEGF on epithelial cells in vivo, we 
injected VEGF (100 ng) or PBS three times per week into 
tumors of wild-type mice exposed to the AOM+DSS proto-
col. Similar to the aforementioned tissue culture experiments, 
the administration of VEGF in vivo resulted in increased tumor 
architecture of tumor vessels (Baish and Jain, 2000; Fig. S3 D). 
The fractal dimension of the normal mucosal capillary net-
work had a mean value of 1.93 ± 0.05, which is characteristic 
for capillaries. In contrast, the fractal dimension of the tumor 
microvasculature had a mean value of 1.73 ± 0.07, which re-
flects the decreased order of the vessel architecture. Upon 
VEGF-Trap treatment, a significant reduction of the fractal 
dimension was found as compared with the control group, 
suggesting a “normalization” of the microvascular vessel archi-
tecture after functional VEGF blockade in vivo (Fig. 4 C).
Furthermore, VEGF-Trap–treated mice had a reduced 
integrin v3 expression in the distal colon and tumors 
showed a significant decrease in intratumoral vessel density 
upon immunohistochemistry for CD31 (Figs. 4, D and E). 
Whereas these alterations of vessel morphology could be at-
tributed to an antiangiogenic effect of VEGF inhibition, the 
reduced tumor scores could also have been a consequence of 
a direct effect of VEGF signaling on VEGFR2-expressing 
tumor cells.
VEGF induces tumor cell proliferation via activation  
of VEGFR2 on IECs
To further characterize effects of VEGF blockade on tumor 
tissue, we performed immunohistochemical double staining. 
Infiltrating MPO+ granulocytes could only rarely be observed 
Figure 3.  Colonic epithelial cells express VEFGR-2 in human IBD and CAC. Tissue sections from control patients or patients with Crohn’s disease, 
ulcerative colitis, sporadic CRC, or CAC were analyzed by confocal microscopy with the indicated antibodies. L, luminal side of intestinal crypt. The experi-
ments were performed twice with similar results. Bar graphs show data generated by counting VEGFR2 and pVEGFR2-positive epithelial cells. Data repre-
sent mean values ± SD (n = 4–8 per group). *, P < 0.01 (A); *, P < 0.005 (B). CRC, sporadic CRC; IBD, IBD including ulcerative colitis and Crohn’s disease. 
Bars, 10 µm.2860 VEGFR links inflammation and tumorigenesis | Waldner et al.
consistent with the idea that VEGF signal transduction plays a 
role at early stages of tumor development in chronic intestinal 
inflammation by controlling proliferation of IECs.
VEGFR2 activation on IEC leads to STAT3 phosphorylation: 
STAT3 is essential for VEGF-mediated tumor growth in vivo
Recent studies have described the activation of STAT3 as a 
critical step during the development of cancer and CAC in 
particular. Concerning CAC, it has been shown that STAT3 
activation  can  be  mediated  via  IL-6  (Bollrath  et  al.,  2009; 
Grivennikov et al., 2009). Interestingly,  VEGFR2 activation has 
also been shown to lead to STAT3 phosphorylation on endo-
thelial cells (Chen et al., 2008). Therefore, we examined STAT3 
phosphorylation in tumors of VEGF-Trap–treated animals 
and controls by immunohistochemistry (Fig. 7 A). In fact, 
growth (Fig. 6 A) and proliferation of tumor cells, as shown 
by Ki67 staining (Fig. 6 B). Thus, we assumed that VEGF has 
a direct effect on tumor proliferation, which is independent 
of angiogenesis.
To further evaluate whether  VEGF receptor 2 is responsible 
for the effect of VEGF on epithelial cell proliferation, we ad-
ministered VEGF to an organ culture of both murine and   
human inflamed colonic tissue. Administration of VEGF led 
to significantly increased proliferation of epithelial cells in 
AOM+DSS colitis and IBD patients and this increase could be 
suppressed through the administration of anti-VEGFR2 anti-
bodies (Fig. 6, C and D). These data further support a direct 
proliferative effect of VEGF on IECs through the activation of 
VEGFR2. As Ki67 staining showed an increased proliferation 
of IECs in IBD patients (Fig. S4, A and B), our findings were 
Figure 4.  Anti-VEGF treatment reduces tumor growth in CAC. (A) After initial endoscopy for the detection of already established tumors after  
4 wk of the AOM+DSS protocol, mice were treated with VEGF-Trap versus control (3 times per week) or a vector expressing sVEGFR1 versus control  
(injected once at week 5). (B) Tumor number, tumor size, and tumor inflammation were measured at the indicated time points after start of each treatment. 
Data represent mean values ± SD (n = 10 per group). The experiment was performed twice with similar results. (C) Mice treated or not treated with VEGF-
Trap were analyzed by optical contrast endoscopy and confocal endoscopy. Fractal dimension and vessel density were measured. Representative images 
of five experiments are shown. Data represent mean values ± SD (n = 5 per group). *, P < 0.05. NBI, narrow band imaging. (D) Multispectral fluorescence 
imaging for integrin v3 expression was performed in untreated and VEGF-Trap–treated animals. Representative images of five experiments are shown. 
(E) The intratumoral vessel density was measured in VEGF-Trap–treated and untreated animals. Representative images of five experiments are shown. 
Data represent mean values ± SD (n = 5 per group). *, P < 0.05. Bars, 100 µm.JEM VOL. 207, December 20, 2010 
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resulted in an increased tumor growth 
in wild-type mice, but not in STAT3 
IEC KO mice (Fig. 7 F). Because of the 
tissue-specific  deletion  of  STAT3  in 
IEC in STAT3 IEC KO mice, these 
differences indicate a direct effect of 
VEGF on tumor rather than endo-
thelial cells.
IL-6 mediates the expression  
of VEGFR2 on colonic epithelial cells during  
chronic inflammation
Among several cytokines, IL-6 and TNF especially have been 
implicated in the pathogenesis of CAC (Becker et al., 2004; 
Popivanova et al., 2008; Bollrath et al., 2009; Grivennikov 
et al., 2009). To analyze the role of IL-6 and TNF during the 
up-regulation of VEGFR2 on epithelial cells, we exposed 
IL-6–deficient  and TNFR1-/TNFR2-deficient  mice,  in 
comparison to wild-type mice, to AOM+DSS colitis. IL-6–
and TNFR1-/TNFR2-deficient  mice  showed  decreased   
tumor development in comparison to wild-type mice (un-
published  data).  Immunohistochemistry  revealed  reduced 
expression of VEGFR2 in colonic epithelial cells of IL-6– 
deficient mice, whereas the inflamed epithelium of TNFR1-/
TNFR2-deficient  and  wild-type  mice  was  positive  for 
VEGFR2 (Fig. 8 A). Although VEGF levels were similar be-
tween wild-type and IL-6–deficient mice,  Western blot analy-
sis revealed a decreased expression of VEGFR2 in tumors of 
IL-6–deficient mice (Fig. 8 B).
Interestingly, IL-6 has been previously shown to induce the 
expression of VEGFR2 on endothelial cells in vitro (Yao et al., 
2006). To test effects of IL-6 on IEC, we incubated colonic 
mucosa of wild-type animals with hyper-IL-6 (hIL-6), a fusion 
protein of IL-6 and soluble IL-6 receptor, in tissue culture ex-
periments. hIL-6 treatment resulted in increased expression of 
VEGFR2 mRNA in the tissue specimens (Fig. 8 C). To further 
VEGF-Trap  treatment  resulted  in  reduced  numbers  of 
pSTAT3+ cells in colonic tumors. Next, we analyzed STAT3 
phosphorylation in an organ culture of colonic tissue sections of 
wild-type mice after incubation with VEGF or PBS (Fig. 7 B). 
Interestingly, the addition of VEGF to the culture medium re-
sulted in increased numbers of pSTAT3+ epithelial cells in 
contrast to culture medium with PBS alone, suggesting the 
ability of VEGF to induce epithelial STAT3 activation in the 
colonic mucosa.
To  show  a  functional  relevance  for  VEGF-mediated 
STAT3 activation, we endoscopically injected VEGF into the 
colonic mucosa of mice with selective inactivation of STAT3 
in IEC (STAT3 IEC KO mice) and wild-type mice exposed 
to the AOM+DSS protocol. 24 h after VEGF injection, we 
found an increased number of Ki67+ epithelial cells in the 
colonic mucosa at the site of VEGF injection in wild-type, 
but not STAT3 IEC KO mice (Fig. 7, C and D). To verify a 
direct effect of  VEGF stimulation on proliferation of IECs, we 
isolated IECs from STAT3 IEC KO and wild-type mice, and 
incubated these cells with VEGF. In these experiments, VEGF 
was able to significantly augment the proliferation of wild-type 
IECs, but not STAT3 KO IECs (Fig. 7 E).
To further characterize the functional consequences of 
increased proliferation of IECs in vivo, we endoscopically 
injected VEGF into tumors of STAT3 IEC KO mice and 
wild-type mice over a period of 2 wk. VEGF injection   
Figure 5.  VEGF directly promotes the 
proliferation of tumor cells. (A) Colons of 
VEGF-Trap and control treated animals were 
analyzed by immunohistochemistry with anti-
bodies specific for the indicated markers. The 
experiment was performed twice with similar 
results. (B) The number of E-Cadherin+/Ki67+ 
double-positive cells was quantified in VEGF-
Trap and control groups. Data are presented 
as mean values of positive cells ± SD (n = 5 
per group). *, P < 0.01. The experiment was 
repeated twice with similar results. (C) VEGF 
(250 ng/ml) was added to tissue cultures of 
AOM+DSS-induced tumors, and proliferation 
and apoptosis of tumor cells was measured 
after staining with the indicated antibodies. 
Representative images from three indepen-
dent experiments are shown. Bars: (A) 10 µm; 
(C) 25 µm.2862 VEGFR links inflammation and tumorigenesis | Waldner et al.
flammation has been shown to increase 
epithelial  proliferation  (MacDonald, 
1992)  and  antiinflammatory  therapy 
has  been  shown  to  reduce  cancer 
growth (Stolfi et al., 2008), the molec-
ular mechanisms that lead to tumor development in chronic 
inflammation are only poorly understood. In this study, we 
show that patients with CAC, in contrast to sporadic CRC 
and control patients, have activated VEGFR2 on IECs. Nota-
bly, inhibition of VEGF signaling had a protective effect in 
a mouse model of CAC associated with a blockade of STAT3-
dependent tumor cell proliferation in vivo, suggesting that 
VEGF signaling in IECs acts as a molecular link between 
inflammation and cancer development.
VEGF, which was initially described as vascular permea-
bility factor (Senger et al., 1983), is an important regulator of 
angiogenesis through the initiation of vessel growth, the inhi-
bition of endothelial cell apoptosis, and the incorporation of 
hematopoietic and endothelial progenitor cells into the de-
veloping vasculature (Ellis and Hicklin, 2008). After the ap-
proval of bevacizumab for the treatment of metastatic sporadic 
CRC, the inhibition of VEGF signaling has been applied to 
various types of cancer and several new therapeutics targeting 
this pathway have been developed, further supporting the im-
portant role of angiogenesis during tumor growth (Jain et al., 
2006; Ferrara et al., 2007).
In our experiments, reduced tumor growth was paral-
leled by a decrease of intratumoral vessel density in anti-
VEGF–treated animals, suggesting an effective inhibition of 
angiogenesis. Furthermore, we analyzed the normalization 
analyze the ability of hIL-6 to induce VEGFR2 expression 
in vivo, we injected hIL-6 into the colonic mucosa of healthy 
mice. In comparison to the injection of PBS, hIL-6 resulted 
in an increased expression of VEGFR2 on IEC (Fig. 8 C), 
suggesting IL-6–dependent regulation of VEGFR2 signaling 
in vivo.
In a final series of studies, we aimed to demonstrate the 
direct effects of hIL-6 on VEGFR2 gene expression in IECs. 
In these experiments, we isolated IECs from VEGFR2 pro-
moter luciferase reporter mice and control mice (purity 
>95%, as determined by E-Cadherin staining; Fig. 8 D). Sub-
sequently, cells were stimulated for 3 h with hIL-6, followed 
by analysis of luciferase reporter gene activity. It was found 
that hIL-6 treatment leads to a significant increase of lumi-
nescence in IECs isolated from VEGFR2 promoter luciferase 
reporter mice (Fig. 8 E), indicating that IL-6 signaling drives 
VEGFR2 gene transcription in IECs.
DISCUSSION
Growing  evidence  supports  an  important  link  between 
chronic inflammation and tumor development. This is nota-
bly evident in patients with IBD such as Crohn’s disease and 
ulcerative colitis, where the risk for CAC increases with the 
duration and severity of intestinal inflammation (Bernstein 
et al., 2001). However, although chronic gastrointestinal in-
Figure 6.  VEGF-mediated proliferation 
of IECs is dependent on VEGFR2 activation. 
(A) VEGF or PBS was injected endoscopically 
into growing tumors of AOM+DSS-treated 
animals 3 times per week. After 2 wk of re-
peated VEGF injections, tumor size was mea-
sured. Data show mean values ± SD (n = 5 per 
group) and represent two independent experi-
ments. *, P < 0.005. (bottom) Endoscopic im-
ages are representative images at day 14 of 
VEGF and PBS injections. (B) Images show 
immunohistochemistry for Ki67 in mice 
treated as in A (top). Bar graphs show quanti-
fication of Ki67+ tumor cells (bottom). Data 
represent mean values ± SD (n = 4 per group). 
The experiment was performed twice with 
similar results. *, P < 0.01. (C and D) Recombi-
nant mouse or human VEGF (final concentra-
tion, 100 ng/ml) was added to inflamed colon 
specimens of AOM+DSS-treated mice (C) or 
endoscopic biopsies of human IBD patients (D). 
Proliferating epithelial cells were measured 
by Ki67 staining. Anti–mouse or anti– 
human blocking VEGFR2 antibodies were 
added where indicated. Representative images 
from three independent experiments per 
group are shown. *, P < 0.05. Bars, 10 µm.JEM VOL. 207, December 20, 2010 
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Because growing 
evidence  supports  a   
role for angiogenesis 
in chronic inflam-
mation  and  auto-
immune disease (Carmeliet, 2003; Costa et al., 2007), the 
inhibition  of VEGF-signaling  has  also  been  proposed  as  a 
promising therapeutic strategy in these disorders. In fact, sev-
eral studies have shown beneficial effects for VEGF-blockade 
in animal models of chronic inflammation (Costa et al., 2007). 
With regard to IBD, Scaldaferri et al. (2009) showed that the 
inhibition of VEGF signaling in DSS colitis reduces inflam-
mation, whereas the overexpression of VEGF leads to an aug-
mentation of intestinal inflammation. These results were not 
only attributed to the role of angiogenesis during the inflam-
matory response, but also to an increased recruitment of leu-
kocytes to the intestinal vascular endothelium. Whereas only 
limited data are available regarding the role of  VEGF in intes-
tinal inflammation, other studies, mainly on experimental 
models of arthritis, have shown several proinflammatory prop-
erties of VEGF, which include leukocyte migration, cytokine 
production, and Th1 cell differentiation (Grosios et al., 2004; 
Mor et al., 2004; Yoo et al., 2005). Therefore, we additionally 
evaluated inflammation in experimental CAC after anti-VEGF 
therapy. In contrast to the study by Scaldaferri et al. (2009), we 
of the tumoral vessel structure after antiangiogenic therapy 
with VEGF-Trap (Baish and Jain, 1998; Baish and Jain, 2000; 
Lin et al., 2008). The concept about a normalization of the 
tumor vasculature is based on a reversal of abnormal struc-
tures of tumor vessels at the microscopic level (Jain, 2005). 
To assess a possible normalization of the functional vascular 
morphology, we used confocal endoscopy in combination 
with optical contrast endoscopy of colonic vessels after i.v. 
injection of the plasma marker FITC-dextran and calculated 
the fractal dimension of the vessel network. Whereas the 
combination of conventional endoscopy with confocal en-
doscopy has been successfully used in patients for the in vivo 
detection of colonic neoplasia (Kiesslich et al., 2004), it has 
not been reported in mice so far and provides the advantage 
that the microvascular structure can be analyzed in living 
animals at several time points without the need to injure the 
animal. Furthermore, the confocal probe can be positioned 
directly next to relevant structure. By using optical contrast 
endoscopy and endomicroscopy, we noted normalization of 
vessel structure upon anti-VEGF therapy. Additionally, anti-
VEGF therapy resulted in an increase of the microvascular 
fractal dimension, reflecting a more homogenous vascular 
network in tumors of treated animals. Therefore, we con-
clude that anti-VEGF therapy effectively reduces angiogen-
esis in experimental CAC.
Figure 7.  VEGF mediates tumor cell pro-
liferation via STAT3 activation. (A) Immuno-
histochemistry of pSTAT3+ tumor cells in control 
or VEGF-Trap–treated animals. Representative 
images of four experiments subjected to 
AOM+DSS treatment. (B) VEGF (250 ng/ml) was 
added to a culture of colon tissue of wild-type 
mice. Phosphorylation of STAT3 was measured. 
Bars, 100 µm. Representative images from 
four independent experiments are shown.  
(C and D) VEGF (100 ng) was injected endo-
scopically into the mucosa of Stat3 fl/fl and 
Stat3 fl/fl + Villin-cre mice. Images show  
immunohistochemistry for Ki67 (C). Bar graphs 
show the number of Ki67+ cells 24 h later.  
(D) Data represent mean values ± SD (n = 4 per 
group). The experiment was performed twice 
with similar results. *, P < 0.05. (E) IECs (purity > 
95%) were isolated from the inflamed colon 
of Stat3 fl/fl and Stat3 fl/fl + Villin-cre mice 
and subsequently stimulated with VEGF (final 
concentration, 100 ng/ml) in vitro. Prolifera-
tion of IECs was analyzed using the WST-1 
proliferation assay after 3 h of VEGF incuba-
tion. Data represent mean values ± SD (n = 6 
per group). Representative images from three 
independent experiments are shown. *, P < 0.05. 
(F) Stat3 fl/fl and Stat3 fl/fl + Villin-cre mice 
were exposed to AOM+DSS treatment. After  
5 wk, VEGF (100 ng) was injected repeatedly 
into size-matched tumors of Stat3 fl/fl and 
Stat3 fl/fl + Villin-cre mice during a period of 
14 d. Tumor growth was measured at indi-
cated time points. Data are mean values ± SD 
(n = 5 per group). The experiment was per-
formed twice with similar results. *, P < 0.05. 
Endoscopic pictures represent images of one 
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cells, which is derived from the detection of 
VEGF receptors on several lines of tumors 
(Jain et al., 2006; Ellis and Hicklin, 2008). 
Because VEGF induces survival, migration, 
and invasion of endothelial cells, the activa-
tion of  VEGF receptors on tumor cells could 
mediate  tumor  growth  and  metastasis.  In 
fact, a recent study by Lichtenberger et al. 
(2010) showed that  VEGFR1 is up-regulated 
in a mouse model of spontaneous skin papil-
lomas and in human squamous cell carcino-
mas and synergizes with EGFR to promote 
the proliferation of this skin neoplasm. Fur-
thermore, in a study on the effect of bevacizumab in patients 
with inflammatory breast cancer, Wedam et al. (2006) found 
phosphorylated VEGFR2  on  tumor  cells  with  decreased 
numbers of pVEGFR2+ tumor cells in patients treated with 
bevacizumab.  The expression of  VEGFR2 has also been shown 
on tumor cells from patients with CRC (Giatromanolaki 
et al., 2007). Nevertheless, a functional significance for VEGFR2 
expression on tumor cells has not been shown so far. In the 
present study, we found an increased expression of total and 
phosphorylated VEGFR2, but not VEGFR1, in intratumoral 
epithelial cells of AOM+DSS-treated mice and in tumor cells of 
colitis-associated neoplasias of humans. Interestingly, VEGFR2 
expression was also elevated in inflamed colonic epithelial 
could not observe an effect of VEGF inhibition on endoscopic 
colitis scores, which may be explained by the duration of the 
experimental procedure. Whereas Scaldaferri et al. (2009) eval-
uated the role of  VEGF in a model of acute DSS colitis, we ex-
posed experimental animals to several cycles of DSS, a protocol 
that is used for the study of chronic colitis (Strober et al., 2002; 
Neufert et al., 2007). These data suggest that  VEGF signaling may 
be important in acute rather than chronic inflammation, at least 
in the intestine, and that the protective effect of anti-VEGF 
therapy on tumor development in our experiments cannot be 
explained by a direct effect on intestinal inflammation.
In addition to its role in angiogenesis and inflammation, 
some studies have proposed a direct effect of VEGF on tumor 
Figure 8.  IL-6 induces the expression of 
VEGFR2 on epithelial cells as a tumor-promoting 
effect during chronic inflammation. (A) Immuno-
histochemistry of VEGFR2 in the inflamed epithelium 
of wild-type, IL-6–deficient, and TNFR-1–/TNFR-2–
deficient mice. Representative images of four experi-
ments. (B) Tissue levels of VEGF were measured in 
IL-6–deficient and wild-type mice by ELISA. VEGFR2-
expression was measured by Western blot analysis. 
Actin was used as a loading control. The experiment 
was performed twice with similar results. (C) Wild-
type colonic tissue was incubated with hIL-6 (10 ng/ml), 
and expression of VEGFR2 mRNA was measured by 
quantitative real-time PCR. Data represent mean 
values ± SD (n = 4 per group). The experiment was 
repeated twice with similar results. *, P < 0.05. 
VEGFR2 expression was measured by immunohisto-
chemistry after endoscopic injection of hIL-6 (100 ng) 
into the mucosa of wild-type mice. Representative 
images from four experiments are shown. (D) Immuno-
cytochemistry for E-Cadherin in isolated IECs from 
control colon and tumor tissue. Images are represen-
tative of four independent experiments. (E) Isolated 
IECs from VEGFR2 luciferase reporter mice were stim-
ulated with hIL-6 (final concentration, 15 µg/ml)  
in vitro. After 3 h of stimulation, luminescence was 
measured using the IVIS Lumina II Imaging System. 
The total flux of photons per second was measured in 
each well. Data show mean values ± SD (n = 6 per 
group) and are representative for 3 independent ex-
periments. *, P < 0.05. Bars, 20 µm.JEM VOL. 207, December 20, 2010 
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was able to induce proliferation of tumor epithelial cells in 
wild-type mice, but not mice with selective inactivation of 
STAT3 in IEC, suggesting that VEGFR signaling controls   
tumor cell proliferation via STAT-3 activation in epithelial 
cells. Based on these findings it is tempting to speculate that 
the beneficial effect of anti-VEGF therapeutics in the pres-
ence of local inflammation is at least partially caused by direct 
anti-tumor effects via STAT-3.
Our data demonstrate that chronic intestinal inflamma-
tion leads to the up-regulation of VEGFR2 on epithelial cells 
and thereby sensitizes these cells to  VEGF-mediated prolifera-
tion via STAT3 activation. Thus,  VEGF signaling links chronic 
inflammation to tumor development in CAC through the 
regulation of angiogenesis and a direct tumor-promoting effect. 
Because VEGF has been implicated in the pathogenesis of 
chronic inflammatory disorders and our data suggest an in-
volvement of  VEGFR2 signaling in tumor initiation and pro-
motion, anti-VEGF therapies might reduce the risk for tumor 
development in patients with IBDs. Furthermore, the expres-
sion of VEGF on tumor cells might be a prognostic marker 
for a successful therapy with anti-VEGF therapeutics.
MATERIALS AND METHODS
Animals and model of CAC. Specific pathogen–free C57BL/6 mice 
(8–10 mo old) were obtained from the central animal facility of Mainz and 
Erlangen. IL-6–deficient and TNF-R1– and R2-deficient mice were obtained 
from The Jackson Laboratory. STAT3 fl/fl mice were provided by S. Akira 
(Osaka University, Osaka, Japan) and crossed with villin-cre mice, which 
were received from D. Gumucio and B. Madison (University of Michigan 
Medical School, Ann Arbor, MI). STAT3 IEC KO mice have been previously 
described (Pickert et al., 2009). VEGF-luc transgenic mice and VEGFR2-luc 
transgenic mice were obtained from Caliper Life Sciences, Inc./Xenogen 
Corporation. CAC was induced as previously described (Neufert et al., 2007). 
In short, mice were injected with a single dose of the mutagenic agent   
7.4 mg/kg AOM (Sigma-Aldrich), followed by three cycles of 2.5% DSS in 
drinking water for 1 wk and normal drinking water for 2 wk. The animal 
studies were conducted at the Universities of Mainz and Erlangen-Nuremberg 
and approved by the Institutional Animal Care and Use Committee of the 
University of Mainz and the State Government of Middle Franconia.
Patients. Paraffin-embedded intestinal specimens from patients with active 
IBD,  CAC,  and  CRC  were  obtained  from  the  Institute  of  Pathology 
(Bayreuth, Germany). Paraffin sections were made and stained with hema-
toxylin and eosin according to routine methods or used for immunohisto-
chemistry as specified in the Immunohistochemistry section. Tissue culture 
experiments were performed with endoscopic biopsy specimens of IBD pa-
tients. The collection of biopsies was approved by the ethical committee and 
the institutional review board of the University of Erlangen-Nuremberg, and 
each patient gave written informed consent.
Narrow band imaging endoscopy, confocal in vivo endoscopy, mul-
tispectral fluorescence, and luminescence imaging. Repeated moni-
toring of tumorigenesis was performed with a high-definition narrow band 
imaging (NBI) endoscope (Exera II; Olympus) that was equipped with a   
2-mm outer diameter optical probe (Storz). Endoscopy of mice and scoring 
of intestinal inflammation, tumor numbers, and tumor size was conducted as 
previously described (Becker et al., 2005). For detection of vessel morphol-
ogy upon NBI endoscopy, single images were obtained and subsequently 
analyzed with ImageJ software at later time points (National Institutes of 
Health). Additionally, a fiber confocal microscope (FCM1000; Leica) with a 
0.9-mm outer diameter probe was used for in vivo confocal endomicroscopy 
cells of AOM+DSS-treated mice and epithelial cells from tis-
sue samples of patients with Crohn’s disease and ulcerative 
colitis, whereas a relatively low VEGFR2 expression was noted 
on tumor cells in sporadic CRC, suggesting an inflammation-
dependent up-regulation of VEGFR2 on IEC. Because tumors 
of VEGF-Trap–treated animals showed decreased numbers of 
proliferating tumor cells, we assumed a direct effect of VEGF 
signaling on tumor growth. This concept was further sup-
ported by an increased proliferation of tumor cells in vitro 
and in vivo through the administration of recombinant  VEGF. 
Furthermore, proliferation of IECs could be suppressed by 
neutralizing anti-VEGFR2 antibodies, suggesting that the 
VEGF–VEGFR2 signaling pathway drives IEC proliferation 
in the AOM+DSS model. Interestingly, it has been shown in 
APC716 mice, a model resembling human familial adenoma-
tous polyposis, that the vascular density in intestinal tumors 
increases only in tumors exceeding a diameter of 1 mm, and 
thus smaller tumors are not dependent on angiogenesis (Seno 
et al., 2002). Because we were able to detect tumors with a 
size >1 mm in diameter in contrast-enhanced endoscopy and 
the reduced tumor scores in anti-VEGF–treated animals were 
mainly dependent on reduced tumor numbers, anti-VEGF 
seemed to be more effective during early stages of tumor de-
velopment, including tumor initiation and promotion, which 
do not rely on angiogenesis.
Because VEGFR2 was expressed on inflamed epithelial 
cells in AOM+DSS colitis and patients with IBD and CAC 
rather than sporadic CRC, we proposed that inflammation 
might lead to an up-regulation of  VEGFR2 on epithelial cells 
and thereby promotes the proliferation of these cells as a 
possible link to tumor development. Consistently, IECs in 
AOM+DSS colitis and IBD patients showed increased prolif-
eration as compared with controls.
Several recent studies have shown that the proinflamma-
tory cytokine IL-6 directly acts on epithelial cells to induce 
the activation of signal transducer and activator of transcrip-
tion 3 (STAT3) and thereby induces the proliferation of epi-
thelial cells in AOM+DSS colitis (Becker et al., 2004; Bollrath 
et al., 2009; Grivennikov et al., 2009). Interestingly, IL-6 has 
also been shown to be a potent inducer of VEGFR2 expres-
sion on vascular endothelial cells (Yao et al., 2006). Thus, we 
analyzed  the  ability  of  IL-6  to  induce  the  expression  of 
VEGFR2 on IEC and noted that hyper-IL-6 induces VEGFR2 
promoter activity in IECs. In addition, whereas the injection 
of hyper-IL-6 into the healthy colonic mucosa of wild-type 
mice resulted in an increased expression of VEGFR2 on epi-
thelial cells, IL-6–deficient mice showed a reduced expression 
of VEGFR2 on epithelial cells in comparison to wild-type 
mice upon AOM+DSS colitis, indicating IL-6–dependent 
regulation  of VEGFR2  expression. VEGFR2  activation  on 
epithelial cells in turn leads to STAT3-dependent prolifera-
tion consistent with previous findings, indicating that VEGF 
can induce the phosphorylation of STAT3 on tumor cells 
in vitro (Lu et al., 2006). However, it remained to be determined 
whether activation of VEGFR2 on tumor cells has functional 
relevance in vivo. In the present study, we observed that  VEGF 2866 VEGFR links inflammation and tumorigenesis | Waldner et al.
Quantitative analysis of gene expression. Total RNA was isolated from 
cells and organs with RNeasy columns (QIAGEN), including DNase I diges-
tion. cDNA was generated using the iScript cDNA Synthesis kit (Bio-Rad 
Laboratories). Quantitative real-time PCR analysis for VEGFR2 and HPRT 
was performed using specific QuantiTect Primer/Probe assays (QIAGEN) and 
QuantiTect Sybr Green (QIAGEN). The expression of  VEGFR2 mRNA was 
analyzed in normal IECs, tumor IECs, and nonepithelial cells of healthy 
mucosa. Gene expression was calculated relative to the house-keeping gene 
-actin using the Ct algorithm.
Protein isolation and ELISA. Plasma samples were prepared from whole 
blood obtained through cardiac puncture of experimental animals. Tissue 
protein was isolated from frozen colon and tumor specimens with the M-PER 
mammalian protein extraction reagent (Thermo Fisher Scientific). Protein 
concentration was analyzed using the Bradford protein assay.
For measurement of VEGF in plasma and tissues, we used a mouse 
VEGF-ELISA kit (Antigenix America Inc.) according to the manufacturer’s 
instructions. Equal amounts of tissue protein lysates and plasma were used.
Western blot analysis. Western blotting was performed as previously de-
scribed (Becker et al., 2003). In short, equal amounts of isolated protein (100 µg) 
were added to 12.5 µl of electrophoresis sample buffer (Roth) and boiled 
according to the manufacturer’s guidelines. Proteins were separated by   
SDS-PAGE on precast gels (4–20% acrylamide; NuSep) and transferred to a 
nitrocellulose  membrane,  which  was  incubated  with  specific  antibodies 
against VEGFR2 (dilution, 1/1,000; Cell Signaling Technology) and -actin 
(dilution,  1/10,000;  Cell  Signaling Technology).  Detection  of  specific 
bands  was  performed  with  the  ECL Western  blotting  analysis  system 
(PerkinElmer).
Histological analysis of colon cross sections. Tissues were isolated from 
mice, infused with 4% paraformaldehyde, and embedded in paraffin. Sections 
from these samples were stained with hematoxylin and eosin. The degree of 
inflammation was graded semiquantitatively on a scale from 0–6 combined 
of inflammatory cell infiltration ranging from 0–3 and tissue damage ranging 
from 0–3 (Neurath et al., 2002; Mudter et al., 2008).
Immunohistochemistry. Cryosections were made of frozen tissue speci-
mens,  fixed  with  4%  paraformaldehyde,  and  sequentially  incubated  with 
methanol, avidin/biotin (Vector Laboratories), and protein-blocking reagent 
(Dako). Primary antibodies specific for CD31 (initial concentration, 0.5 mg/ml; 
dilution, 1/500; eBioscience), E-Cadherin (initial concentration, 0.5 mg/ml; 
dilution,  1/200;  eBioscience), VEGFR2  (dilution,  1/500;  Cell  Signaling;   
Abcam;  eBioscience),  phosphoVEGFR2  (dilution,  1/500;  Cell  Signaling   
Abcam), pSTAT3 (dilution: 1/500; Cell Signaling), myeloperoxidase (initial 
concentration, 2 mg/ml; dilution, 1/20; Abcam), F4/80 (initial concentration,   
0.5 mg/ml; dilution, 1/500; BD), CD4 (dilution, 1/200; BD), and Ki67 (dilu-
tion, 1/200; Dako) were dissolved in TBST/0.5% BSA and incubated over-
night at 4°C. For negative controls, the primary antibody was omitted. In the 
case of VEGFR2 and pVEGFR2, additional negative controls were per-
formed by administration of the blocking peptide during primary antibody 
incubation (VEGFR2 and pVEGFR2; dilution, 1/10; Cell Signaling Tech-
nology), furthermore, anti-VEGFR2 and -pVEGFR2 antibodies from differ-
ent manufacturers were tested to ensure specificity. Subsequently, slides were 
incubated with biotinylated secondary antibodies and streptavidin-HRP and 
stained  with Tyramide  (Cy3  and  FITC)  according  to  the  manufacturer’s 
guidelines (PerkinElmer). Nuclei were counterstained with DAPI contained 
in Vectashield mounting medium (Vector Laboratories). Next, brightfield 
(IX70; Olympus) or confocal microscopy (SP5; Leica) was performed. Quan-
tification of positive cells was performed with ImageJ software (National In-
stitutes of Health) and counted per longitudinal crypt.
In vitro organ culture. Intestinal tumors, mucosal sections of experimental 
animals or colonic biopsies of patients with IBD were placed on steel grids 
in an organ culture chamber at 37°C with a 95% O2/5% CO2 atmosphere in 
of the microvascular architecture. The probe was fed through a manipulation 
sheath of the endoscope and positioned endoscopically to the area of interest. 
For the detection of vessel morphology, 100 µl of FITC-Dextran (70 kD,   
5 mg/ml; Sigma-Aldrich) were injected into the tail vein of the experimental 
animal as a plasma marker and images were recorded for offline analysis.
Evaluation of the vessel structure including vessel density, mean vessel seg-
ment length, and fractal dimension of vessels, was performed with ImageJ soft-
ware from recorded images of NBI-endoscopy and endomicroscopy (Fig. S3).
Multispectral fluorescence imaging of integrin v3 was performed after 
injection of fluorescence imaging agent IntegriSense into the tail vein of se-
lected experimental animals (100 µl per animal; VisEn Medical) with the 
Maestro imaging system (Intas).
Analysis of VEGF or VEGFR2 expression in VEGF-luc or VEGFR2-luc 
transgenic mice was performed at the indicated time points. Therefore, mice were 
analyzed  with  the  IVIS  Lumina  II  Imaging  System  (Caliper  Life  Sciences)   
10 min after intraperitoneal injection of firefly luciferin (150 mg/kg; Promega).
Administration of VEGF-Trap, sVEGFR1, VEGF, and IL-6 in CAC. 
Treatment of C57BL/6 mice with VEGF-Trap, sVEGFR1, or VEGF was ini-
tiated after endoscopic detection of already established tumors at week 4 of 
the AOM+DSS protocol. Animals were then equally assigned to a treatment 
group and a control group to ensure matching tumor scores before the ad-
ministration of each compound. VEGF-Trap (provided by Regeneron Phar-
maceuticals Inc.) was injected subcutaneously 3 times per week at a dosage of 
25 mg/kg for a duration of 4 wk. The control group received hFc (25 mg/kg). 
An adenoviral vector expressing sVEGFR1 has been previously described 
(Scaldaferri et al., 2009) and was injected into the tail vein at a concentration 
of 4 mg/kg. The control group received a control vector alone (LacZ) at a 
concentration of 4 mg/kg. In some experiments, VEGF was endoscopically 
injected into already established tumors or the mucosa (50–100 µl of a 1 µg/ml 
solution), whereas PBS was injected into tumors of control mice.
Hyper-IL-6 was generated as previously described (Fischer et al., 1997) 
and endoscopically injected into the colonic mucosa of untreated C57 BL/6 
mice (100 µl of a 1 µg/ml solution).
Isolation of IECs and in vitro experiments. Tumors and tumor-free co-
lons of wild-type or reporter gene mice were incubated at 37°C in HBSS 
containing 2 mM EDTA, 1 mM EGTA, and 1% FCS for 15 min to separate 
epithelial cells. Isolated cells were filtered through a 40-µm cell strainer (BD) 
and cultured at 37°C in complete RPMI 1640 medium.
To confirm the purity of the separation, IECs were fixed to glass slides 
in a Cytospin2-centrifuge (Shandon). After centrifugation at 500 rpm for   
5 min, slides were removed and dried for 2 h. Immunohistochemistry for 
E-Cadherin was performed as described in the Immunohistochemistry section, 
and the ratio of E-Cadherin–positive cells was counted. A purity of >95% 
could be confirmed for IEC isolation from tumor and tumor-free tissue.
For the stimulation of IECs, mouse VEGF (Miltenyi Biotec) was added 
at a final concentration of 100 ng/ml to the culture medium; alternatively 
hIL-6 was added at a final concentration of 15 µg/ml. The analysis of IEC-
proliferation was performed with the WST-1 cell proliferation reagent 
(Roche) according to the manufacturer’s instructions. Luminescence of IECs 
from VEGFR2-luc transgenic mice was measured 10 min after addition of 
150 mg/kg firefly luciferin (Promega) to the cell culture medium with the 
IVIS Lumina II Imaging System (Caliper Life Sciences) according to the 
manufacturer’s instructions.
FACS analysis of isolated IECs. Epithelial cells from control colon tissue 
and tumor tissue of AOM+DSS-treated mice were isolated as described 
above. Analysis of VEGFR2 expression on epithelial cells by FACS was per-
formed with FITC-labeled antibodies to E-Cadherin (eBioscience) and bio-
tin-labeled antibodies to VEGFR2 (eBioscience). After antibody incubation 
at 4°C for 30 min, cells were washed with PBS/1% FCS. Subsequently, cells 
were incubated with streptavidin-Cy3 (Dianova) for 10 min and washed 
twice in PBS/1% FCS before FACS analysis, which was performed with the 
FACSCanto II System (BD).JEM VOL. 207, December 20, 2010 
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